Croda Q1 Report 2024
Steve Foots, Chief Executive Officer, said:
“Consumer Care has made an encouraging start to the year with growth across all business units and a significant improvement in North America. Life Sciences continues to experience more challenging market conditions, particularly in Crop Protection. Overall, we are on track to meet our previously stated Group guidance for the full year. We are focused on executing our strategy, accelerating the conversion of our exciting Pharma pipeline, and investing for the future whilst carefully monitoring costs, with a clear set of priorities that will drive our near-term performance.”
Highlights
- Group sales of £409m, down 10% at constant currency versus a strong Q1 2023 comparator
- Group sales up 8% versus Q4 2023, excluding Covid-19 lipid sales in the previous quarter
- Continue to expect Group FY24 adjusted PBT to be between £260m and £300m